Quick Facts
| Property | Value |
|---|---|
| Category | Neuropeptide / Immune-Modulating Peptide |
| Risk Level | Experimental |
| Administration | Intranasal or Subcutaneous |
| Typical Frequency | 1–4x Daily Intranasal / 1–3x Daily SubQ |
| Estimated Half-Life | Short-Acting Peptide |
| Primary Research Interest | Inflammation / Respiratory Support / Immune Signaling |
This material is provided strictly for educational and informational purposes related to peptide research and experimental neuroimmune compounds. Vasoactive Intestinal Peptide (VIP) is a biologically active signaling peptide capable of influencing inflammatory, vascular, neurological, respiratory, and immune-modulating pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Intranasal Reconstitution Guide
- Vial Size: 5 mg
- Dilutant Type: BAC Water
- Total Dilutant Amount: 30 mL
- Final Concentration: 0.167 mg/mL
Mixing Instructions:
• Reconstitute the vial with 3 mL BAC water
• Transfer the entire contents into a 30 mL nasal spray bottle
• Add an additional 27 mL BAC water
Approximate spray delivery:
• ~29 mcg per spray
• Spray bottle delivery volume assumed to be ~0.175 mL per spray
2. Intranasal Route & Protocol
VIP is commonly researched as an intranasal peptide for respiratory, inflammatory, immune-modulating, and neurological applications.
- Primary Route: Intranasal
- Typical Delivered Amount: 1–2 sprays per nostril
- Frequency: 1–4 times daily
- Cycle Length: Indefinite / PRN for illness-related research
- Special Notes: VIP is commonly researched for respiratory, inflammatory, immune-modulating, and mold-related illness applications, particularly in protocols focused on chronic inflammatory response syndromes. Because VIP may strongly influence vasodilation and autonomic signaling, some users report temporary flushing, lightheadedness, headaches, or changes in blood pressure sensitivity. Intranasal delivery is generally preferred within the experimental community because it is less invasive and may provide more direct respiratory and neurological exposure pathways. Researchers commonly emphasize beginning with conservative dosing because some individuals appear unusually sensitive to VIP-related signaling effects.
3. Subcutaneous Reconstitution Guide
- Vial Size: 5 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 2.00 mg/mL
At this concentration:
• 10 mcg = 0.005 mL (0.5 units)
• 100 mcg = 0.050 mL (5.0 units)
4. Subcutaneous Route & Protocol
VIP is also researched as a systemic subcutaneous injectable peptide for broader immune and inflammatory signaling applications.
- Primary Route: SubQ Injection
- Typical Delivered Amount: 10–100 mcg per dose
- Frequency: 1–3 times daily
- Cycle Length: Indefinite / PRN for illness-related research
- Special Notes: Subcutaneous VIP is generally discussed as producing more systemic whole-body effects compared to intranasal administration and may therefore increase the likelihood of vasodilatory side effects such as flushing, dizziness, rapid heartbeat, or transient blood-pressure changes. Some experimental users report that SQ administration feels significantly stronger even at relatively low doses, making conservative dose escalation especially important. Compared to intranasal delivery, subcutaneous administration is typically considered less targeted toward respiratory pathways but potentially more systemically active. Because VIP signaling intersects with immune, inflammatory, neurological, and vascular systems simultaneously, unusually sensitive individuals may react strongly even to modest dosing.
5. Summary
Vasoactive Intestinal Peptide (VIP) is an experimental neuroimmune signaling peptide researched for its potential effects on inflammation, respiratory pathways, immune modulation, autonomic balance, and vascular signaling.
Research interest in VIP commonly centers around chronic inflammatory conditions, respiratory support pathways, mold-related illness protocols, and neurological-autonomic regulation.
6. Mechanism of Action
VIP functions as a broad neuroimmune signaling peptide capable of influencing inflammatory regulation, vascular tone, autonomic signaling, respiratory pathways, and immune communication.
- Immune-modulating signaling
- Anti-inflammatory pathway interaction
- Respiratory pathway support
- Vasodilation signaling
- Neurological-autonomic regulation
- Cytokine modulation
The peptide is commonly researched for its wide-ranging regulatory effects across multiple body systems.
7. Potential Benefits
- Potential inflammatory-modulation support
- Possible respiratory pathway support
- Potential autonomic nervous system regulation
- Possible immune-signaling balance support
- Potential neurological support applications
- Possible mold-related illness research applications
8. Potential Risks / Side Effects
Experimental
- Flushing
- Lightheadedness
- Rapid heartbeat
- Headaches
- Blood-pressure fluctuations
- Nasal irritation (intranasal use)
- Injection site irritation (SubQ use)
- Potential overstimulation of autonomic signaling pathways
9. Half-Life
VIP is commonly discussed as a relatively short-acting peptide requiring repeated administration for sustained effects.
Intranasal administration is often discussed as potentially producing faster localized respiratory and neurological effects, while SubQ administration may produce broader systemic activity.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Maintain sterile handling practices during preparation
- Discard solutions showing discoloration or contamination
11. Contraindications / Warnings
- Severe hypotension or unstable blood pressure
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Use alongside multiple vasoactive compounds without supervision
- Severe autonomic instability concerns
12. Research References
- PubMed
- NIH Publications
- Immunology literature
- Peer-reviewed neuroimmune and respiratory journals